Literature DB >> 3742833

The effects of exogenous melatonin on endocrine function in man.

J Wright, M Aldhous, C Franey, J English, J Arendt.   

Abstract

At two different times of year (spring and autumn) an oral preparation of the pineal neurohormone melatonin, or placebo, was administered to 12 healthy volunteers (10 men and two women in spring: the same group minus one man in autumn) daily at 1700 h for 1 month (spring), or 3 weeks (autumn) using a double-blind cross-over protocol. The daily dose was 2 mg melatonin in 5 ml corn-oil, and placebo consisted of the vehicle only. In spring the anterior pituitary hormones LH, PRL, GH together with T4, cortisol, testosterone and melatonin were measured at 1- to 6-h intervals for 24 h in plasma on the day following the last dose. In autumn PRL, cortisol and melatonin levels were measured on the last day of treatment. Subjective fatigue, mood and sleep records were kept throughout the studies. Melatonin increased early evening fatigue and actual sleep, but had no effect on mood: these results are reported in full elsewhere. Melatonin administration had no effect on the levels or 24-h rhythm of LH, GH, T4, testosterone or cortisol. An earlier fall in the nocturnal PRL was observed on both occasions. Overall PRL levels were higher in spring than in autumn. In five of the subjects, the secretion of endogenous melatonin was advanced by 1-3 h in the presence of exogenous melatonin. These observations suggest that the potential therapeutic use of melatonin as a hypnotic or in the treatment of jet lag is unlikely to be complicated by undesirable endocrine effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742833     DOI: 10.1111/j.1365-2265.1986.tb01641.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

Review 1.  The therapeutic potential of melatonin: a review of the science.

Authors:  Samir Malhotra; Girish Sawhney; Promila Pandhi
Journal:  MedGenMed       Date:  2004-04-13

2.  Melatonin administered in the afternoon decreases next-day luteinizing hormone levels in men: lack of antagonism by flumazenil.

Authors:  R Luboshitzky; Z Shen-Orr; T Shochat; P Herer; P Lavie
Journal:  J Mol Neurosci       Date:  1999-02       Impact factor: 3.444

3.  Melatonin regulates somatotrope and lactotrope function through common and distinct signaling pathways in cultured primary pituitary cells from female primates.

Authors:  Alejandro Ibáñez-Costa; José Córdoba-Chacón; Manuel D Gahete; Rhonda D Kineman; Justo P Castaño; Raúl M Luque
Journal:  Endocrinology       Date:  2014-12-29       Impact factor: 4.736

4.  Acute administration of melatonin at two opposite circadian stages does not change responses to gonadotropin releasing hormone, thyrotropin releasing hormone and ACTH in healthy adult males.

Authors:  P Paccotti; M Terzolo; M Torta; A Vignani; M Schena; A Piovesan; A Angeli
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

5.  Twenty-four hour melatonin pattern in acromegaly: effect of acute octreotide administration.

Authors:  A A Sinisi; D Pasquali; A D'Apuzzo; D Esposito; T Venditto; T Criscuolo; A De Bellis; A Bellastella
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

Review 6.  Chronomedicine and type 2 diabetes: shining some light on melatonin.

Authors:  Andrew C Forrestel; Susanne U Miedlich; Michael Yurcheshen; Steven D Wittlin; Michael T Sellix
Journal:  Diabetologia       Date:  2016-12-16       Impact factor: 10.122

Review 7.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

8.  Melatonin improves memory acquisition under stress independent of stress hormone release.

Authors:  Ulrike Rimmele; Maria Spillmann; Carmen Bärtschi; Oliver T Wolf; Cora S Weber; Ulrike Ehlert; Petra H Wirtz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

9.  Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly.

Authors:  M Terzolo; A Piovesan; A Alì; A Codegone; A Pia; G Reimondo; M Torta; P Paccotti; G Borretta; A Angeli
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

10.  Increased sensitivity of the circadian system to light in delayed sleep-wake phase disorder.

Authors:  Lauren A Watson; Andrew J K Phillips; Ihaia T Hosken; Elise M McGlashan; Clare Anderson; Leon C Lack; Steven W Lockley; Shantha M W Rajaratnam; Sean W Cain
Journal:  J Physiol       Date:  2018-10-25       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.